09688

16.3905.53%
PK

Peter Karl Wirth

Independent Director

Mr. Peter Karl Wirth, Esq., JD, had been Chairman and Director at Syros Pharmaceuticals, Inc. since January 30, 2017 until February 28, 2025. He was Chairman at Forma Therapeutics Holdings, Inc. Since November 2012 until October 14, 2022. He serves as Director at Centrexion Therapeutics Corporation. Mr. Wirth is a Senior Consultant with Quan Capital since August 2018. He had been a Senior Advisor at Zai Lab Limited since 2015. From November 2011 to April 2014, Mr. Wirth served as co-founder, president and director of Lysosomal Therapeutics, Inc. He served as the Chief Legal Officer and Executive Vice President of Corporate Development & Legal of Genzyme Oncology, Inc. (also known as Genzyme Molecular Oncology) since September 1996 and served as its Secretary. He served as Chief Legal Officer and Executive Vice President of Legal & Corporate Development at Sanofi Biosurgery since September 1996 and served as its Secretary. Mr. Wirth served as Executive Vice President of Corporate Development & Legal at Genzyme Corporation since September 1996 and served as its Secretary and Outside General Counsel since 1982. From January 1996 to May 2011, Mr. Wirth served as Senior Executive of Genzyme with responsibility for its legal, corporate development and risk management functions and its molecular oncology and polymer research divisions. He served as Chief Legal Officer and Executive Vice President of Genzyme General. He served as the Head of Biotechnology Practice Group at Palmer & Dodge LLP. He served as Of Counsel of Palmer & Dodge LLP and was its Partner from 1982 to September 1996. He served as Secretary of Genzyme Tissue Repair. He was employed at Genzyme Surgical Products. He served as Chief Legal Officer of Genzyme Corporation from September 1996 to May 2008 and served as its Chief Risk Officer. Mr. Wirth served as an Executive Vice President with responsibility for Genzyme Corporation's Drug Discovery and Development Business from 2001 to October 2005. He joined Genzyme in 1996. During his time at Genzyme, Mr. Wirth had senior management responsibility for its legal function, corporate development function, molecular oncology division, polymer drug discovery and development division and enterprise risk management function. He was instrumental in helping build Genzyme from a small start-up to a diversified, multi-billion dollar enterprise with more than 12,000 employees in locations spanning the globe. Mr. Wirth's areas of legal expertise include venture capital financings, institutional private placements, public offerings, off-balance sheet R&D financings such as RDLPs and SWORDS, corporate collaborations, joint ventures and mergers and acquisitions. He served as an Outside General Counsel for a number of public and private biotechnology companies, including companies working in the areas of neuroscience, immunology, non-absorbable pharmaceuticals, gene therapy, structure-based drug design, NMR imaging agents and bioseparations. Mr. Wirth had been an Executive Chairman of ZappRx, Inc. from August 2016 to May 2018 and serves as its Senior Advisor. He has been the Chairman and Director of FORMA Therapeutics, Inc. since November 2012. He has been an Independent Director of ZAI Lab Limited since May 2020 and was Director since 2017. He served as a Director of Aura Biosciences, Inc., from December 2013 to December 2017. He served as a Director of Synageva BioPharma Corp. from June 2012 to June 22, 2015. He served as a Director of EPIX Pharmaceuticals, Inc. since August 2001. From 1975 to 1995, Mr. Wirth practiced law at Palmer & Dodge. Mr. Wirth was a 2012 Advanced Leadership Fellow at Harvard University. Mr. Wirth received his B.A. from the University of Wisconsin - Madison in 1972 and his J.D. from Harvard Law School in 1975.

Positions